Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ELDER PHARMA   MYLAN
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
MYLAN
Dec-18
ELDER PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3803,945-   
Low Rs1882,171-   
Sales per share (Unadj.) Rs489.21,815.3-  
Earnings per share (Unadj.) Rs-3.249.3-  
Cash flow per share (Unadj.) Rs14.4389.2-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs376.51,963.8-  
Shares outstanding (eoy) m20.54514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.61.7 34.5%   
Avg P/E ratio x-89.362.0 -143.9%  
P/CF ratio (eoy) x19.77.9 250.8%  
Price / Book Value ratio x0.81.6 48.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,8321,573,481 0.4%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m2,1790-   
Avg. sales/employee Rs Th026,685.0-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0724.6-  
INCOME DATA
Net Sales Rs m10,048933,975 1.1%  
Other income Rs m2570-   
Total revenues Rs m10,305933,975 1.1%   
Gross profit Rs m2,921241,678 1.2%  
Depreciation Rs m361174,877 0.2%   
Interest Rs m2,75644,921 6.1%   
Profit before tax Rs m6021,880 0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m125-3,481 -3.6%   
Profit after tax Rs m-6525,361 -0.3%  
Gross profit margin %29.125.9 112.3%  
Effective tax rate %209.1-15.9 -1,314.5%   
Net profit margin %-0.62.7 -23.9%  
BALANCE SHEET DATA
Current assets Rs m9,240521,531 1.8%   
Current liabilities Rs m9,998380,253 2.6%   
Net working cap to sales %-7.515.1 -49.9%  
Current ratio x0.91.4 67.4%  
Inventory Days Days12884 153.5%  
Debtors Days Days60293 644.9%  
Net fixed assets Rs m13,642181,176 7.5%   
Share capital Rs m206497 41.4%   
"Free" reserves Rs m7,5280-   
Net worth Rs m7,7331,010,390 0.8%   
Long term debt Rs m4,8891,090,535 0.4%   
Total assets Rs m22,8822,710,259 0.8%  
Interest coverage x1.01.5 68.7%   
Debt to equity ratio x0.61.1 58.6%  
Sales to assets ratio x0.40.3 127.4%   
Return on assets %11.82.6 453.5%  
Return on equity %-0.82.5 -33.6%  
Return on capital %22.33.2 701.7%  
Exports to sales %3.10-   
Imports to sales %0.40-   
Net fx Rs m1810-   
CASH FLOW
From Operations Rs m11,754194,080 6.1%  
From Investments Rs m-561-100,318 0.6%  
From Financial Activity Rs m-6,762-90,414 7.5%  
Net Cashflow Rs m5,4661,608 340.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 82.88 Rs / USD

Compare ELDER PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ELDER PHARMA With: BROOKS LAB  AARTI DRUGS  S.S.ORGANICS  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  



Today's Market

Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3% Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3%(10:30 am)

Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.